Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 10Endocrine 10Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Head and Neck Cancers - Salivary Gland 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3FAPI-46 2tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1fludarabine phosphate 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Lactones 1Interleukin-2 1Interleukin-13 1Immunotherapy 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Cryosurgery 1Biopsy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × surufatinib × Head & Neck × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡